{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:09:19Z","timestamp":1787792959996,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["NIH T32 DK007742"],"award-info":[{"award-number":["NIH T32 DK007742"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>The demand for orthotopic liver transplantation (OLT) is projected to increase, which indicates a need to expand the liver donor pool. We aimed to investigate the use of hepatitis B virus (HBV)\u2013positive grafts and the outcomes of recipients undergoing OLT with HBV\u2010positive grafts. We conducted a retrospective cohort study analyzing all deceased donors and OLT recipients in the Organ Procurement and Transplantation Network database from January 1999 through March 2021. Donor HBV status was positive if hepatitis B surface antigen was positive or HBV nucleic acid testing was detectable. Recipients of HBV\u2010positive allografts were matched 1:5 to recipients of HBV\u2010negative allografts based on recipient and donor age, transplant year, recipient sex, donation after circulatory death, recipient location, and Model for End\u2010Stage Liver Disease score at transplant. Among the 185,212 potential donors, 422 (0.2%) were HBV positive, and 265 (63%) of the HBV\u2010positive grafts were transplanted (14 of 265 [5.3%] in HBV\u2010positive recipients). The overall discard rate for HBV\u2010positive donors of 37.2% (157\/422) remained significantly higher than the discard rate for HBV\u2010negative donors of 26.5% (49,026\/185,212) during the study period (<jats:italic toggle=\"yes\">p<\/jats:italic>\u2009&lt;\u20090.001). Recipients of HBV\u2010positive (<jats:italic toggle=\"yes\">n<\/jats:italic> = 209) grafts had similar mortality (log\u2010rank, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.47) and graft loss (log\u2010rank, <jats:italic toggle=\"yes\">p\u2009=<\/jats:italic> 0.72) rates to the matched recipients of HBV\u2010negative allografts (<jats:italic toggle=\"yes\">n<\/jats:italic> = 1045). The 3\u2010year graft survival rate was 77.9% for the HBV\u2010positive group and 79.7% in the matched HBV\u2010negative group. Based on this analysis, transplant recipients of HBV\u2010positive liver allografts do not experience increased rates of mortality or graft loss. One strategy that may help expand the donor pool and lower the waitlist mortality rate is using HBV\u2010positive allografts.<\/jats:p>","DOI":"10.1002\/lt.26543","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T04:13:36Z","timestamp":1658117616000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Use and outcomes of hepatitis B virus\u2013positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021"],"prefix":"10.1097","volume":"29","author":[{"given":"Saad Emhmed","family":"Ali","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-6077","authenticated-orcid":false,"given":"Philip","family":"Vutien","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Washington Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Andrew","family":"Bonham","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Landis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Washington Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8234-4485","authenticated-orcid":false,"given":"Paul","family":"Kwo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Esquivel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA"},{"name":"Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"R1-20250501","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.3748\/wjg.v25.i47.6799","article-title":"Expanding the donor pool: hepatitis C, hepatitis B and human immunodeficiency virus\u2010positive donors in liver transplantation","volume":"25","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R2-20250501","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamasurg.2014.2038","article-title":"Survival benefit of solid\u2010organ transplant in the United States","volume":"150","year":"2015","journal-title":"JAMA Surg"},{"key":"R3-20250501","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/ajt.13823","article-title":"National outcomes of liver transplantation for model for end\u2010stage liver disease score >\/=40: the impact of share 35","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"R4-20250501","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/TP.0000000000002956","article-title":"A comprehensive review of outcome predictors in low MELD patients","volume":"104","year":"2020","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"R5-20250501","first-page":"193","article-title":"OPTN\/SRTR 2018 annual data report","volume":"20","year":"2020","journal-title":"Liver Am J Transplant"},{"key":"R6-20250501","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.30831","article-title":"Chronic hepatitis B prevalence among foreign\u2010born and U.S.\u2010born adults in the United States, 1999\u20132016","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"R7-20250501","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R8-20250501","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/jvh.12880","article-title":"Viral activity and outcome of hepatitis B surface antigen\u2010positive grafts in deceased liver transplantation","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"R9-20250501","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2011.09.016","article-title":"Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"R10-20250501","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jvh.12972","article-title":"Long\u2010term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen\u2010positive donors in a Chinese population","volume":"25","year":"2018","journal-title":"J Viral Hepat"},{"key":"R11-20250501","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jhep.2014.05.003","article-title":"Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"R12-20250501","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/cid\/ciz001","article-title":"Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011\u20132016","volume":"69","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R13-20250501","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta\u2010analysis","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"R14-20250501","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/ajt.13187","article-title":"Solid organ transplantation from hepatitis B virus\u2010positive donors: consensus guidelines for recipient management","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"R15-20250501","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/lt.23774","article-title":"Use of hepatitis B surface antigen\u2010positive grafts in liver transplantation: a matched analysis of the US national database","volume":"20","year":"2014","journal-title":"Liver Transpl"},{"key":"R16-20250501","doi-asserted-by":"crossref","first-page":"245","DOI":"10.6002\/ect.2012.0095","article-title":"Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus","volume":"11","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"R17-20250501","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SLA.0000000000005071","article-title":"Expanding the donor Pool: first use of hepatitis B virus Nat positive solid organ allografts into seronegative recipients","volume":"274","year":"2021","journal-title":"Ann Surg"},{"key":"R18-20250501","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s11605-020-04759-4","article-title":"Cost\u2010effectiveness of utilization of hepatitis B virus\u2010positive liver donors for HBV\u2010negative transplant recipients","volume":"25","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"R19-20250501","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/SLA.0000000000001352","article-title":"From bench to bill: how a transplant nuance became 1 of only 57 laws passed in 2013","volume":"263","year":"2016","journal-title":"Ann Surg"},{"key":"R20-20250501","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/ajt.16886","article-title":"HOPE in action: a prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV","volume":"22","year":"2022","journal-title":"Am J Transplant"},{"key":"R21-20250501","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.14309\/ajg.0000000000000583","article-title":"Use of HCV\u2010positive livers in HCV\u2010negative recipients","volume":"115","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R22-20250501","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/lt.23600","article-title":"Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen\u2010positive liver transplant candidates","volume":"19","year":"2013","journal-title":"Liver Transpl"},{"key":"R23-20250501","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/jlts.2000.18702","article-title":"An efficacy and cost\u2010effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy","volume":"6","year":"2000","journal-title":"Liver Transpl"},{"key":"R24-20250501","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0168-8278(01)00080-0","article-title":"Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis","volume":"34","year":"2001","journal-title":"J Hepatol"},{"key":"R25-20250501","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/lt.20701","article-title":"Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis","volume":"12","year":"2006","journal-title":"Liver Transpl"},{"key":"R26-20250501","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"R27-20250501","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","article-title":"Long\u2010term outcomes in hepatitis B: the REVEAL\u2010HBV study","volume":"11","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R28-20250501","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","year":"2011","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lt.26543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lt.26543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/lt.26543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:00:54Z","timestamp":1746115254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/lt.26543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.26543","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"2022-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}